» Articles » PMID: 28074409

Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified?

Overview
Journal Drugs Aging
Specialties Geriatrics
Pharmacology
Date 2017 Jan 12
PMID 28074409
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Depression in the context of dementia is common and contributes to poorer outcomes in individuals and those who care for them. Non-pharmacological treatments are the preferred initial approach to managing these symptoms but data in support of these are scarce. There are a number of pharmacological treatment options available to clinicians but efficacy is uncertain and concern about potential side effects in an aging and vulnerable population needs to be taken into consideration. This review aims to provide a concise overview of pharmacological treatments for depression in dementia. Antidepressants are the mainstay of pharmacological treatment for clinically significant depression in the general population but evidence to support their use in dementia is mixed. Trials of antidepressants should generally be reserved for individuals with depression where the symptoms are distressing and surpass the threshold for major depression. Acetylcholinesterase inhibitors and memantine are effective in the symptomatic treatment of Alzheimer's disease but current evidence does not support their use to treat depressive symptoms in dementia. Similarly, antipsychotics and mood stabilizers have no proven efficacy for depression and the risk of adverse effects seems to outweigh any potential benefit. Pain can be a frequent problem in dementia and may have significant effects on behavior and mood. Preliminary evidence supports a role of adequate analgesia in improving mood in people with dementia.

Citing Articles

Serum alkaline phosphatase was independently associated with depression in patients with cerebrovascular disease.

Tao X, Yang C, He J, Liu Q, Wu S, Tang W Front Psychiatry. 2023; 14:1184673.

PMID: 37469359 PMC: 10352498. DOI: 10.3389/fpsyt.2023.1184673.


Imbalance of multiple neurotransmitter pathways leading to depression-like behavior and cognitive dysfunction in the triple transgenic mouse model of Alzheimer disease.

Zhang M, Liu L, Xu Y, Wang W, Qiu N, Zhang F Metab Brain Dis. 2023; 38(7):2465-2476.

PMID: 37256468 DOI: 10.1007/s11011-023-01242-2.


The Prevalence of Atypical Antipsychotics, Antidepressants, and Benzodiazepines Use in Dementia Patients in King Abdulaziz Medical City.

Basaeed A, Wafia G, Alhidri B, Sindi L, Hakami A, Jastaniah N Cureus. 2022; 14(10):e30460.

PMID: 36407231 PMC: 9673055. DOI: 10.7759/cureus.30460.


Tasks and Activities of an Effective Collaborative Dementia Care Management Program in German Primary Care.

Muhlichen F, Michalowsky B, Radke A, Platen M, Mohr W, Thyrian J J Alzheimers Dis. 2022; 87(4):1615-1625.

PMID: 35491783 PMC: 9277686. DOI: 10.3233/JAD-215656.


Concordance of self- and informant-rated depressive symptoms in nursing home residents with Dementia: cross-sectional findings.

OSullivan J, Schweighart R, Lech S, Kessler E, Tegeler C, Teti A BMC Psychiatry. 2022; 22(1):241.

PMID: 35382790 PMC: 8981933. DOI: 10.1186/s12888-022-03876-5.


References
1.
Rapp M, Schnaider-Beeri M, Wysocki M, Guerrero-Berroa E, Grossman H, Heinz A . Cognitive decline in patients with dementia as a function of depression. Am J Geriatr Psychiatry. 2010; 19(4):357-63. PMC: 3062696. DOI: 10.1097/JGP.0b013e3181e898d0. View

2.
McShane R, Areosa Sastre A, Minakaran N . Memantine for dementia. Cochrane Database Syst Rev. 2006; (2):CD003154. DOI: 10.1002/14651858.CD003154.pub5. View

3.
Lockhart I, Orme M, Mitchell S . The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis. Dement Geriatr Cogn Dis Extra. 2011; 1(1):212-27. PMC: 3199891. DOI: 10.1159/000330032. View

4.
Husebo B, Achterberg W, Flo E . Identifying and Managing Pain in People with Alzheimer's Disease and Other Types of Dementia: A Systematic Review. CNS Drugs. 2016; 30(6):481-97. PMC: 4920848. DOI: 10.1007/s40263-016-0342-7. View

5.
Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M . Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503):2112-7. PMC: 2850264. DOI: 10.1016/S0140-6736(05)67889-0. View